Actualización
Carcinogénesis estrogénica en el cáncer de mama
Actualización los hallazgos recientes relacionados con la exposición a los estrógenos y el riesgo de cáncer de mama, sus mecanismos e implicancias clínicas.
Autor/a: Dres. James D. Yager, Nancy E. Davidson
Fuente: Estrogen Carcinogenesis in Breast Cancer. N Eng J Med. 354(3):270-282. 19 de enero, 2006
Indice
1. Bibliografía
2. Desarrollo
2. Santen R. Endocrine-responsive cancer. In: Larson PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia: W.B. Saunders, 2003:1797-833.
3. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285. [Erratum, N Engl J Med 2001;344:1804.]
4. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-1226.
5. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
6. Onland-Moret NC, Kaaks R, Van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003;88:1394-1399.
7. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast-cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-1865.
8. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-765.
9. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-318.
10. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer: Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059. [Erratum, Lancet 1997;350:1484.]
11. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast-cancer risk. JAMA 2000;283:485-491. [Erratum, JAMA 2000;284:2597.]
12. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454.
13. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
15. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
16. Post-menopausal oestrogen therapy. Lyon, France: International Agency for Research on Cancer, 1999. (IARC scientific publications no. 72.)
17. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427. [Erratum, Lancet 2003;362:1160.]
18. Speroff L. The Million Women Study and breast cancer. Maturitas 2003;46:1-6.
19. Gambacciani M, Genazzani AR. The study with a million women (and hopefully fewer mistakes). Gynecol Endocrinol 2003;17:359-362.
20. Olsson H. What can we learn from the Million Women Study. Maturitas 2003;46:87-89.